Aprea Therapeutics, Inc. Board of Directors

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Dr. Oren Gilad Ph.D.

Dr. Oren Gilad Ph.D.

Co-Founder, CEO, President & Director

Dr. Michel Afargan Ph.D.

Dr. Michel Afargan Ph.D.

Head of Pharmacology Development

Dr. Dansu Li Ph.D.

Dr. Dansu Li Ph.D.

Head of Technology

Mr. Brian Wiley

Mr. Brian Wiley

Senior Vice President of Corporate Development & Strategy

Dr. Lars B. Abrahmsen Ph.D.

Dr. Lars B. Abrahmsen Ph.D.

Senior VP & Chief Scientific Officer

Mr. John P. Hamill CPA

Mr. John P. Hamill CPA

Senior VP, CFO, Principal Accounting Officer & Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.